Literature DB >> 9924302

Internal resection of posterior uveal melanomas.

P J Kertes1, J C Johnson, G A Peyman.   

Abstract

AIMS: To evaluate the safety and efficacy of internal resection in the treatment of malignant melanoma of the choroid.
METHODS: 32 consecutive patients with histopathologically proved malignant choroidal melanomas were treated with internal resection. 29 of the 32 (90.6%) tumours were within 2 disc diameters of the optic nerve or fovea. The surgery was performed at two university centres by one of the authors. Follow up was between 1 and 85 months (mean 40.1 months).
RESULTS: Three patients developed distant metastases and died of malignant melanoma (metastatic and mortality rate 9.4%). In one case, distant metastases developed in association with an intraocular recurrence. There have been no other intraocular recurrences. The most common postoperative complication was vitreous haemorrhage, which occurred in 12 patients (37.5%); cataract occurred in eight eyes; and three patients developed retinal detachment postoperatively. Three of the operated eyes have been enucleated (9.4%); a total of four (12.5%) have lost light perception. 10 patients (31.2%) had visual acuities of 6/60 or better and 18 of 32 (56.3%) were between 6/120 and light perception.
CONCLUSION: These data suggest that the internal resection of posterior uveal melanomas is a reasonable globe saving management option. This treatment modality is particularly well suited to elevated tumours in close proximity to the optic nerve or fovea.

Entities:  

Mesh:

Year:  1998        PMID: 9924302      PMCID: PMC1722373          DOI: 10.1136/bjo.82.10.1147

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  48 in total

1.  Improved iodine-125 plaque design in the treatment of choroidal malignant melanoma.

Authors:  J C Hill; R Sealy; D Shackleton; C Stannard; J Korrubel; E Hering; C Loxton
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

2.  Melanomas of the eye and other noncutaneous sites: epidemiologic aspects.

Authors:  J Scotto; J F Fraumeni; J A Lee
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

3.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Authors:  S A Rosenberg; P Aebersold; K Cornetta; A Kasid; R A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; S L Topalian
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

4.  Episcleral plaque radiotherapy in the treatment of uveal melanomas.

Authors:  Z Petrovich; G Luxton; B Langholz; M A Astrahan; P E Liggett
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Treatment of juxtapapillary melanomas.

Authors:  P K Lommatzsch; R Lommatzsch
Journal:  Br J Ophthalmol       Date:  1991-12       Impact factor: 4.638

6.  Cobalt-60 plaque radiotherapy vs enucleation for posterior uveal melanoma.

Authors:  J J Augsburger; J W Gamel; K Lauritzen; L W Brady
Journal:  Am J Ophthalmol       Date:  1990-05-15       Impact factor: 5.258

7.  A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988.

Authors:  M Diener-West; B S Hawkins; J A Markowitz; A P Schachat
Journal:  Arch Ophthalmol       Date:  1992-02

Review 8.  Management of posterior uveal melanoma.

Authors:  J A Shields; C L Shields; L A Donoso
Journal:  Surv Ophthalmol       Date:  1991 Nov-Dec       Impact factor: 6.048

9.  Partial lamellar sclerouvectomy for ciliary body and choroidal tumors.

Authors:  J A Shields; C L Shields; P Shah; V Sivalingam
Journal:  Ophthalmology       Date:  1991-06       Impact factor: 12.079

10.  Internal choroidectomy of posterior uveal melanomas under a retinal flap.

Authors:  G A Peyman; N C Nelson; C L Paris; K J Blinder; W A Alturki; U R Desai
Journal:  Int Ophthalmol       Date:  1992-11       Impact factor: 2.031

View more
  10 in total

1.  Eye-wall resection.

Authors:  D H Char; T Miller; J B Crawford
Journal:  Trans Am Ophthalmol Soc       Date:  2000

2.  Uveal tumour resection.

Authors:  D H Char; T Miller; J B Crawford
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

3.  [Endoresection following proton beam irradiation of large uveal melanomas].

Authors:  N E Bechrakis; S Höcht; P Martus; K M Kreusel; J Heese; M H Foerster
Journal:  Ophthalmologe       Date:  2004-04       Impact factor: 1.059

4.  Respond to: Safe endoresection.

Authors:  Mehdi Modarres; Asgari Rezanejad; Khalil Ghasemi Falavarjani
Journal:  Indian J Ophthalmol       Date:  2015-03       Impact factor: 1.848

5.  Outcomes of primary endoresection for choroidal melanoma.

Authors:  Andre A C Vidoris; Andre Maia; Marcia Lowen; Melina Morales; Jordan Isenberg; Bruno F Fernandes; Rubens N Belfort
Journal:  Int J Retina Vitreous       Date:  2017-11-06

6.  Surgical Approach in Intraocular Tumors

Authors:  Ahmet Kaan Gündüz; Ibadulla Mirzayev
Journal:  Turk J Ophthalmol       Date:  2022-04-28

Review 7.  Local treatment failure after globe-conserving therapy for choroidal melanoma.

Authors:  Melinda Y Chang; Tara A McCannel
Journal:  Br J Ophthalmol       Date:  2013-05-03       Impact factor: 4.638

8.  Clinicopathologic correlations in eyes enucleated after uveal melanoma resection with positive surgical margins.

Authors:  Yousuf Khalifa; Thomas M Aaberg; Thomas M Aaberg; Hans E Grossniklaus
Journal:  Indian J Ophthalmol       Date:  2007 Sep-Oct       Impact factor: 1.848

9.  Recurrence and massive extraocular extension of choroidal malignant melanoma after vitrectomy and endoresection.

Authors:  Mehdi Modarres; Asgari Rezanejad; Khalil Ghasemi Falavarjani
Journal:  Indian J Ophthalmol       Date:  2014-06       Impact factor: 1.848

10.  Prognostic factors of choroidal melanoma in Slovenia, 1986-2008.

Authors:  Boris Jancar; Marjan Budihna; Brigita Drnovsek-Olup; Katrina Novak Andrejcic; Irena Brovet Zupancic; Dusica Pahor
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.